Alembic Pharmaceuticals receives final approval for Olmesartan Medoxomil Tablets & Medoxomil with Hydrochlorothiazide Tablets

Capital Market 

From USFDA

Alembic Pharmaceuticals has received USFDA final approval for Olmesartan Medoxomil Tablets, 5mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5 mg, 40/12.5 mg and 40/25 mg. The approved ANDAs are indicated for the treatment of hypertension.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Alembic Pharmaceuticals receives final approval for Olmesartan Medoxomil Tablets & Medoxomil with Hydrochlorothiazide Tablets

From USFDA

From USFDA

Alembic Pharmaceuticals has received USFDA final approval for Olmesartan Medoxomil Tablets, 5mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5 mg, 40/12.5 mg and 40/25 mg. The approved ANDAs are indicated for the treatment of hypertension.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22